Research analysts at Wells Fargo & Company started coverage on shares of Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) in a research report issued to clients and investors on Monday, MarketBeat.com reports. The brokerage set an "overweight" rating and a $28.00 price target on the stock. Wells Fargo & Company's target price would suggest a potential upside of 20.22% from the stock's previous close.
Several other equities analysts have also commented on KMTS. The Goldman Sachs Group initiated coverage on Kestra Medical Technologies in a research note on Monday. They set a "neutral" rating and a $24.00 price target on the stock. Piper Sandler began coverage on shares of Kestra Medical Technologies in a report on Monday. They set an "overweight" rating and a $27.00 target price on the stock. Finally, Stifel Nicolaus initiated coverage on shares of Kestra Medical Technologies in a report on Monday. They issued a "buy" rating and a $28.00 price target for the company. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, Kestra Medical Technologies presently has an average rating of "Moderate Buy" and a consensus price target of $27.67.
Check Out Our Latest Analysis on Kestra Medical Technologies
Kestra Medical Technologies Price Performance
NASDAQ:KMTS traded down $0.73 during midday trading on Monday, hitting $23.29. The stock had a trading volume of 62,011 shares, compared to its average volume of 275,704. Kestra Medical Technologies has a one year low of $20.00 and a one year high of $26.06.
About Kestra Medical Technologies
(
Get Free Report)
We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.
Read More
Before you consider Kestra Medical Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kestra Medical Technologies wasn't on the list.
While Kestra Medical Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
